Immunology

Kalinke Lab

Ulrich Kalinke
Head

Prof. Dr. Ulrich Kalinke

Projects

Here you can gain an insight into the projects of the Kalinke Lab in the field of immunology. In particular, immune responses in acute hepatitis and encephalitis are being investigated in order to develop innovative therapies on this basis.


Kalinke Lab
Immunology

Immunological sensing of cytomegalovirus (CMV)

The project investigates how HCMV is recognized by the immune system and which mechanisms the virus uses to camouflage itself. The aim is to understand the immune reactions and develop therapies for severely affected patients.

Kalinke Lab
Immunology

Regulation of acute hepatitis

The project investigates immune reactions in viral hepatitis, in particular the role of hepatocytes and myeloid cells. The aim is to understand immune processes in the liver and to develop diagnostic approaches for the clinic.

Kalinke Lab
Immunology

Virus control within the CNS

The project investigates the immune response of the central nervous system in viral infections, in particular the role of type I IFN, microglia and monocytes in the development of encephalitis and their influence on seizures and hippocampal damage.

Kalinke Lab
Immunology

Towards the molecular mechanism of HBV vaccination non-responsiveness

The project will investigate the immunological and genetic causes of vaccination failure in 5% of HBV-vaccinated individuals in order to develop new strategies to improve vaccination protection.

Kalinke Lab
Immunology

Cell-selective delivery of active compounds

The project is developing methods to specifically transport antibiotics into cells such as alveolar macrophages, which are important in Mycobacterium tuberculosis infections. The aim is to overcome resistance and reduce side effects.

Kalinke Lab
Immunology

Towards the development of novel cell therapy options for MSMD patients

The project is developing iPSC-based therapies for MSMD patients, a genetic disease with mutations in the IFN-γ signaling pathway that lead to severe mycobacterial infections. The aim is to improve the treatment prognosis.